Unicycive Therapeutics Faces Securities Class Action Over FDA Delays

The lawsuit, filed by the law firm Bronstein, Gewirtz & Grossman, LLC, claims that Unicycive failed to audit its manufacturing partners or verify compliance with FDA standards. According to the complaint, these omissions left the firm without a reasonable basis for its public optimism, as the vendor had not addressed previously cited deficiencies. Consequently, the company’s silence on these manufacturing risks allegedly obscured the likelihood of delays in the regulatory approval process for oxylanthanum carbonate.

Investors seeking to participate in the litigation have until November 2, 2026, to apply for lead plaintiff status. While the firm operates on a contingency fee basis, meaning legal costs are only recovered if the case succeeds, shareholders are not required to serve as lead plaintiffs to remain eligible for a potential settlement. Interested parties can review the complaint and contact Peretz Bronstein or Nathan Miller at 917-590-0911 for further details regarding the recovery process.